



## **Yposkesi to host roundtable on challenges in gene therapy manufacturing at the Cell and Gene Meeting on the Mesa, October 2-4**

**As more gene therapies advance to clinical trials, participants will discuss which are the best strategies for manufacturing to scale**

**Wednesday, October 2, 12 noon PDT in Carlsbad (CA)**

**Corbeil-Essonnes, France, September 24, 2019** – [Yposkesi](#), a leading Contract Development and Manufacturing Organization (CDMO) for preferred access and reserved capacity for cGMP grade viral vector production, today announces it will host a roundtable luncheon on 'Addressing today's gene therapy manufacturing challenges' at the [Cell and Gene Meeting on the Mesa](#), organized by the Alliance for Regenerative Medicine.

"As an increasing number of cell and gene therapies move from the lab to the clinic, manufacturing is becoming an essential part of a company's success in delivering its product to patients," said Michael Lehmicke, director, science & industry affairs at the Alliance for Regenerative Medicine. "There is considerable dialogue going on in this space on how to manufacture at scale. The Meeting at the Mesa is a great opportunity to convene the leading experts in this area to continue that discussion and learn best practices."

Yposkesi has invited four guest speakers to the roundtable: Vijay Chiruvolu, SVP of global process development at Kite Pharma, Reed Clark, SVP at Ultragenyx Gene Therapy, Scott Cross, VP of vector operations at Orchard Therapeutics and Fraser Wright, professor of pediatrics at Stanford University. In discussing the challenges industry faces in gene therapy manufacturing, they will also talk about the innovations in processing and analytics being developed.

Yposkesi's roundtable luncheon is scheduled for Wednesday, October 2 at 12 noon at the Park Hyatt Aviara Resort Golf Club & Spa, Carlsbad, (CA). It is open to Cell and Gene Therapy Meeting on the Mesa attendees only.

"We are delighted to assemble top specialists in a roundtable discussion on innovations in processes and analytics that will tackle the capacity bottleneck in viral vector manufacturing," said Alain Lamproye, CEO of Yposkesi. "Yposkesi has invested significantly in introducing innovations into its industrial platform, enabling us to forge ahead on building the capacity to deliver commercial batches of gene therapies to regulatory standards. We look forward to sharing our advances in bioprocessing with global industry players at The Cell and Gene Therapy Meeting on the Mesa in October."

To register for Yposkesi's roundtable on 'Addressing today's gene therapy manufacturing challenges', please contact the [events team](#) at the Alliance for Regenerative Medicine.

### **About Yposkesi**

Yposkesi is a leading Contract Development & Manufacturing Organization (CDMO) for gene therapy vector manufacturing. Created in November 2016 in Corbeil-Essonnes (France) as a spin-off from the world-class gene therapy pioneer Genethon, Yposkesi provides integrated services covering bioprocess development (USP & DSP) from small/pilot to large-scale production, analytical development, GMP manufacturing of lentiviral and AAV



vectors and regulatory support. Its current facility consists of a 50,000<sup>2</sup> ft (approx. 5,000<sup>2</sup> m) building, operating multiple manufacturing suites for bulk drug substance and fill&finish. By 2021 it will have increased its global footprint to 100,000<sup>2</sup> ft (approx. 10,000<sup>2</sup> m) with a second large-scale facility designed for EMA and FDA compliance. Capitalizing on the more than 25 years' expertise of Genethon, Yposkesi invests significantly in innovation in bioprocessing to deliver on high-quality projects, cost-effectively.

[www.yposkesi.com](http://www.yposkesi.com)

---

**Media contact**

**Andrew Lloyd & Associates**

Carol Leslie

[carol@ala.com](mailto:carol@ala.com)

UK and US: +44 1273 675 100

France: +33 1 56 54 07 00

---